BACKGROUND AND AIMS: Increasingly, people start a gluten-free diet (GFD) without a clear celiac disease (CD) diagnosis. Human leukocyte antigen (HLA) genotyping is useful in ruling out CD in patients with equivocal results of serologic testing or small-bowel biopsy (SBB), but its utility and the clinical features of patients on self-treated GFD (ST-GFD) are largely unknown. METHODS: Retrospective study of single tertiary care center cohort compared 137 patients on ST-GFD and 443 patients with well-defined CD. We compared HLA genotype, symptoms, serologic and SBB results, and response to GFD between the 2 groups. Analysis used univariate logistic regression modeling, adjusted for age and sex. RESULTS: Patients with ST-GFD presented more often with diarrhea (P<0.001), abdominal distention (P<0.001), flatulence (P=0.002), cramping (P=0.02), itchy skin (P=0.02), oral inflammation (P=0.04), and constipation (P=0.01) and less often with anemia (P<0.001) or malaise (P=0.02) than CD patients. In addition, 41% did not carry DQ2.5 and DQ8 versus 6% of CD patients (P<0.001). Only 2% of ST-GFD patients had SBB clearly consistent with CD. Family history of CD showed no difference between groups (P=0.77). Although CD patients had a statistically higher rate of GFD benefit, both groups had a high responsiveness rate (98% vs. 94%; P=0.03). CONCLUSIONS: HLA genotyping is useful in evaluating patients on an ST-GFD. Although confirmed CD is rare in self-treated patients, most still report benefit from GFD regardless of DQ2 and DQ8 status. Nonceliac gluten sensitivity may play a role.
BACKGROUND AND AIMS: Increasingly, people start a gluten-free diet (GFD) without a clear celiac disease (CD) diagnosis. Human leukocyte antigen (HLA) genotyping is useful in ruling out CD in patients with equivocal results of serologic testing or small-bowel biopsy (SBB), but its utility and the clinical features of patients on self-treated GFD (ST-GFD) are largely unknown. METHODS: Retrospective study of single tertiary care center cohort compared 137 patients on ST-GFD and 443 patients with well-defined CD. We compared HLA genotype, symptoms, serologic and SBB results, and response to GFD between the 2 groups. Analysis used univariate logistic regression modeling, adjusted for age and sex. RESULTS:Patients with ST-GFD presented more often with diarrhea (P<0.001), abdominal distention (P<0.001), flatulence (P=0.002), cramping (P=0.02), itchy skin (P=0.02), oral inflammation (P=0.04), and constipation (P=0.01) and less often with anemia (P<0.001) or malaise (P=0.02) than CDpatients. In addition, 41% did not carry DQ2.5 and DQ8 versus 6% of CDpatients (P<0.001). Only 2% of ST-GFDpatients had SBB clearly consistent with CD. Family history of CD showed no difference between groups (P=0.77). Although CDpatients had a statistically higher rate of GFD benefit, both groups had a high responsiveness rate (98% vs. 94%; P=0.03). CONCLUSIONS:HLA genotyping is useful in evaluating patients on an ST-GFD. Although confirmed CD is rare in self-treated patients, most still report benefit from GFD regardless of DQ2 and DQ8 status. Nonceliac gluten sensitivity may play a role.
Authors: Daniëlle A W M van der Windt; Petra Jellema; Chris J Mulder; C M Frank Kneepkens; Henriëtte E van der Horst Journal: JAMA Date: 2010-05-05 Impact factor: 56.272
Authors: Marjorie M Walker; Joseph A Murray; Jukka Ronkainen; Pertti Aro; Tom Storskrubb; Mauro D'Amato; Brian Lahr; Nicholas J Talley; Lars Agreus Journal: Gastroenterology Date: 2010-04-13 Impact factor: 22.682
Authors: Jessica R Biesiekierski; Evan D Newnham; Peter M Irving; Jacqueline S Barrett; Melissa Haines; James D Doecke; Susan J Shepherd; Jane G Muir; Peter R Gibson Journal: Am J Gastroenterol Date: 2011-01-11 Impact factor: 10.864
Authors: K Kaukinen; K Turjanmaa; M Mäki; J Partanen; R Venäläinen; T Reunala; P Collin Journal: Scand J Gastroenterol Date: 2000-09 Impact factor: 2.423
Authors: Anna Sapone; Karen M Lammers; Vincenzo Casolaro; Marcella Cammarota; Maria Teresa Giuliano; Mario De Rosa; Rosita Stefanile; Giuseppe Mazzarella; Carlo Tolone; Maria Itria Russo; Pasquale Esposito; Franca Ferraraccio; Maria Cartenì; Gabriele Riegler; Laura de Magistris; Alessio Fasano Journal: BMC Med Date: 2011-03-09 Impact factor: 8.775
Authors: Ann E Almazar; Nicholas J Talley; Joseph J Larson; Elizabeth J Atkinson; Joseph A Murray; Yuri A Saito Journal: Eur J Gastroenterol Hepatol Date: 2018-02 Impact factor: 2.566
Authors: Anna Tavakkoli; Suzanne K Lewis; Christina A Tennyson; Benjamin Lebwohl; Peter H R Green Journal: Dig Dis Sci Date: 2013-12-28 Impact factor: 3.199
Authors: Carlo Catassi; Armin Alaedini; Christian Bojarski; Bruno Bonaz; Gerd Bouma; Antonio Carroccio; Gemma Castillejo; Laura De Magistris; Walburga Dieterich; Diana Di Liberto; Luca Elli; Alessio Fasano; Marios Hadjivassiliou; Matthew Kurien; Elena Lionetti; Chris J Mulder; Kamran Rostami; Anna Sapone; Katharina Scherf; Detlef Schuppan; Nick Trott; Umberto Volta; Victor Zevallos; Yurdagül Zopf; David S Sanders Journal: Nutrients Date: 2017-11-21 Impact factor: 5.717